Eckert and Ziegler (EUZ.DE)

Executive Summary

Eckert & Ziegler is a leading German provider of isotope solutions and radiopharmaceuticals, serving the diagnostic and therapeutic nuclear medicine markets. With over 25 years of experience, the company has established a robust supply chain for medical isotopes, including the critical Mo-99/Tc-99m generator systems, and has expanded into the high-growth theranostics segment. The company's integrated business model—spanning isotope production, contract development and manufacturing (CDMO), and proprietary drug development—positions it as a key enabler of the emerging radiopharmaceutical therapy (RPT) market. Strong demand for targeted radionuclide therapies in oncology, particularly for prostate cancer and neuroendocrine tumors, is driving revenue growth, while ongoing capacity expansions in Europe and the U.S. support future scaling.

Upcoming Catalysts (preview)

• Q3 2026FDA or EMA approval decision on proprietary theranostic candidate (e.g., EZZ-001 for prostate cancer)65% success
• H2 2026Completion of new isotope production facility in the U.S. (increased supply capacity)90% success
• TBDMajor partnership or licensing deal with a large pharma company for radiopharmaceutical development50% success